Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) - PubMed (original) (raw)
Clinical Trial
. 2015 Feb;172(2):484-93.
doi: 10.1111/bjd.13348. Epub 2014 Dec 11.
Collaborators, Affiliations
- PMID: 25132411
- DOI: 10.1111/bjd.13348
Clinical Trial
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
A Blauvelt et al. Br J Dermatol. 2015 Feb.
Abstract
Background: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection. Self-administration by pre-filled syringe (PFS) can offer patients clinical benefits of a drug, with increased convenience.
Objectives: To assess efficacy, safety and usability of secukinumab administration via PFS in subjects with moderate-to-severe plaque psoriasis.
Materials and methods: Subjects in this phase 3 trial were randomized 1 : 1 : 1 to secukinumab 300 or 150 mg or matching placebo. Results to week 12 are presented here. Each treatment was delivered using a PFS once weekly to week 4, and again at week 8. Co-primary endpoints were secukinumab superiority over placebo for week 12 PASI 75 (≥ 75% reduction in Psoriasis Area and Severity Index) and IGA mod 2011 (2011 modified Investigator's Global Assessment) 0/1 response rates. Secondary endpoints included PFS usability, determined by observer rating of successful, hazard-free self-injection and subject rating of acceptability by the Self-Injection Assessment Questionnaire (SIAQ).
Results: Co-primary endpoints were met, with demonstration of superiority for each secukinumab dose vs. placebo at week 12 (PASI 75: 75·9%, 69·5% and 0% for secukinumab 300 mg, 150 mg and placebo; IGA mod 2011 0/1: 69·0%, 52·5% and 0%, respectively; P < 0·0001 for all comparisons vs. placebo). PFS usability was high: 100% of subjects successfully self-administered treatment at week 1, and subjects reported high SIAQ-assessed acceptability of the PFS throughout the trial. No new/unexpected safety signals were observed.
Conclusions: Secukinumab administration by PFS was effective, with an acceptable safety profile and high usability. The PFS provides a reliable, convenient form of secukinumab administration in subjects with moderate-to-severe plaque psoriasis.
© 2014 British Association of Dermatologists.
Similar articles
- Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C; JUNCTURE study group. Paul C, et al. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90. doi: 10.1111/jdv.12751. Epub 2014 Sep 22. J Eur Acad Dermatol Venereol. 2015. PMID: 25243910 Clinical Trial. - Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Papp KA, et al. Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18. Br J Dermatol. 2013. PMID: 23106107 Clinical Trial. - Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C. Gottlieb AB, et al. J Drugs Dermatol. 2016 Oct 1;15(10):1226-1234. J Drugs Dermatol. 2016. PMID: 27741340 Clinical Trial. - Secukinumab (AIN457) for the treatment of psoriasis.
López-Ferrer A, Vilarrasa E, Puig L. López-Ferrer A, et al. Expert Rev Clin Immunol. 2015;11(11):1177-88. doi: 10.1586/1744666X.2015.1095092. Epub 2015 Oct 1. Expert Rev Clin Immunol. 2015. PMID: 26428036 Review. - Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP. Garnock-Jones KP. Am J Clin Dermatol. 2015 Aug;16(4):323-330. doi: 10.1007/s40257-015-0143-7. Am J Clin Dermatol. 2015. PMID: 26202871 Review.
Cited by
- Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy.
Blauvelt A, Langley RG, Branigan PJ, Liu X, Chen Y, DePrimo S, Ma K, Scott B, Campbell K, Muñoz-Elías EJ, Papp KA. Blauvelt A, et al. JID Innov. 2024 Jun 5;4(5):100287. doi: 10.1016/j.xjidi.2024.100287. eCollection 2024 Sep. JID Innov. 2024. PMID: 39114670 Free PMC article. - A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients with Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp.
Kyrmanidou E, Kemanetzi C, Stavros C, Trakatelli MG, Patsatsi A, Madia X, Ignatiadi D, Kalloniati E, Apalla Z, Lazaridou E. Kyrmanidou E, et al. Dermatol Pract Concept. 2024 Apr 1;14(2):e2024119. doi: 10.5826/dpc.1402a119. Dermatol Pract Concept. 2024. PMID: 38810083 Free PMC article. - Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management.
Bilal H, Khan MN, Khan S, Fang W, Chang W, Yin B, Song NJ, Liu Z, Zhang D, Yao F, Wang X, Wang Q, Cai L, Hou B, Wang J, Mao C, Liu L, Zeng Y. Bilal H, et al. Mycology. 2023 Oct 20;15(1):30-44. doi: 10.1080/21501203.2023.2265664. eCollection 2024. Mycology. 2023. PMID: 38558839 Free PMC article. Review. - Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience.
Yıldırım FE, Hapa FA. Yıldırım FE, et al. Postepy Dermatol Alergol. 2024 Feb;41(1):49-55. doi: 10.5114/ada.2023.135757. Epub 2024 Feb 28. Postepy Dermatol Alergol. 2024. PMID: 38533357 Free PMC article. - Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials.
Zhang Y, Yang Z, Gong J, Shi D. Zhang Y, et al. Front Med (Lausanne). 2024 Mar 6;11:1353893. doi: 10.3389/fmed.2024.1353893. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38510451 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous